BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Asokan R, Hua J, Young KA, Gould HJ, Hannan JP, Kraus DM, Szakonyi G, Grundy GJ, Chen XS, Crow MK, Holers VM. Characterization of human complement receptor type 2 (CR2/CD21) as a receptor for IFN-alpha: a potential role in systemic lupus erythematosus. J Immunol 2006;177:383-94. [PMID: 16785534 DOI: 10.4049/jimmunol.177.1.383] [Cited by in Crossref: 55] [Cited by in F6Publishing: 56] [Article Influence: 3.4] [Reference Citation Analysis]
Number Citing Articles
1 Vandendriessche S, Cambier S, Proost P, Marques PE. Complement Receptors and Their Role in Leukocyte Recruitment and Phagocytosis. Front Cell Dev Biol 2021;9:624025. [PMID: 33644062 DOI: 10.3389/fcell.2021.624025] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
2 Kooijman S, Brummelman J, van Els CACM, Marino F, Heck AJR, Mommen GPM, Metz B, Kersten GFA, Pennings JLA, Meiring HD. Novel identified aluminum hydroxide-induced pathways prove monocyte activation and pro-inflammatory preparedness. J Proteomics 2018;175:144-55. [PMID: 29317357 DOI: 10.1016/j.jprot.2017.12.021] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 3.8] [Reference Citation Analysis]
3 Puri TS, Quigg RJ. The Many Effects of Complement C3- and C5-Binding Proteins in Renal Injury. Seminars in Nephrology 2007;27:321-37. [DOI: 10.1016/j.semnephrol.2007.02.005] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 1.2] [Reference Citation Analysis]
4 Harley JB, James JA. Everyone comes from somewhere: systemic lupus erythematosus and Epstein-Barr virus induction of host interferon and humoral anti-Epstein-Barr nuclear antigen 1 immunity. Arthritis Rheum 2010;62:1571-5. [PMID: 20178135 DOI: 10.1002/art.27421] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 1.2] [Reference Citation Analysis]
5 Hu Z, Ni J, Cao Y, Liu X. Newcastle Disease Virus as a Vaccine Vector for 20 Years: A Focus on Maternally Derived Antibody Interference. Vaccines (Basel) 2020;8:E222. [PMID: 32422944 DOI: 10.3390/vaccines8020222] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
6 He YG, Pappworth IY, Rossbach A, Paulin J, Mavimba T, Hayes C, Kulik L, Holers VM, Knight AM, Marchbank KJ. A novel C3d-containing oligomeric vaccine provides insight into the viability of testing human C3d-based vaccines in mice. Immunobiology 2018;223:125-34. [PMID: 29017821 DOI: 10.1016/j.imbio.2017.10.002] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.4] [Reference Citation Analysis]
7 Chang N, Li TT, Kim JJ, Landolt-marticorena C, Fortin PR, Gladman DD, Urowitz MB, Wither JE. Interferon-α induces altered transitional B cell signaling and function in Systemic Lupus Erythematosus. Journal of Autoimmunity 2015;58:100-10. [DOI: 10.1016/j.jaut.2015.01.009] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 3.3] [Reference Citation Analysis]
8 Wan H, Hu J, Tian X, Chang S. Molecular dynamics simulations of wild type and mutants of human complement receptor 2 complexed with C3d. Phys Chem Chem Phys 2013;15:1241-51. [DOI: 10.1039/c2cp41388d] [Cited by in Crossref: 42] [Cited by in F6Publishing: 12] [Article Influence: 4.7] [Reference Citation Analysis]
9 Kim D, Niewiesk S. Synergistic induction of interferon α through TLR-3 and TLR-9 agonists identifies CD21 as interferon α receptor for the B cell response. PLoS Pathog 2013;9:e1003233. [PMID: 23516365 DOI: 10.1371/journal.ppat.1003233] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 1.7] [Reference Citation Analysis]
10 Ricklin D, Lambris JD. Exploring the complement interaction network using surface plasmon resonance. Adv Exp Med Biol 2007;598:260-78. [PMID: 17892218 DOI: 10.1007/978-0-387-71767-8_19] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 1.0] [Reference Citation Analysis]
11 Kulik L, Chen K, Huber BT, Holers VM. Human complement receptor type 2 (CR2/CD21) transgenic mice provide an in vivo model to study immunoregulatory effects of receptor antagonists. Molecular Immunology 2011;48:883-94. [DOI: 10.1016/j.molimm.2010.12.019] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 1.2] [Reference Citation Analysis]
12 Young KA, Chen XS, Holers VM, Hannan JP. Isolating the Epstein-Barr virus gp350/220 binding site on complement receptor type 2 (CR2/CD21). J Biol Chem 2007;282:36614-25. [PMID: 17925391 DOI: 10.1074/jbc.M706324200] [Cited by in Crossref: 20] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
13 Lavoie TB, Kalie E, Crisafulli-Cabatu S, Abramovich R, DiGioia G, Moolchan K, Pestka S, Schreiber G. Binding and activity of all human alpha interferon subtypes. Cytokine 2011;56:282-9. [PMID: 21856167 DOI: 10.1016/j.cyto.2011.07.019] [Cited by in Crossref: 113] [Cited by in F6Publishing: 106] [Article Influence: 11.3] [Reference Citation Analysis]
14 Shaw CD, Storek MJ, Young KA, Kovacs JM, Thurman JM, Holers VM, Hannan JP. Delineation of the complement receptor type 2-C3d complex by site-directed mutagenesis and molecular docking. J Mol Biol 2010;404:697-710. [PMID: 20951140 DOI: 10.1016/j.jmb.2010.10.005] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 1.3] [Reference Citation Analysis]
15 Woods KM, Pope MR, Hoffman SM, Fleming SD. CR2+ marginal zone B cell production of pathogenic natural antibodies is C3 independent. J Immunol 2011;186:1755-62. [PMID: 21187447 DOI: 10.4049/jimmunol.1002059] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 0.8] [Reference Citation Analysis]
16 Li K, Okemefuna AI, Gor J, Hannan JP, Asokan R, Holers VM, Perkins SJ. Solution structure of the complex formed between human complement C3d and full-length complement receptor type 2. J Mol Biol 2008;384:137-50. [PMID: 18804116 DOI: 10.1016/j.jmb.2008.08.084] [Cited by in Crossref: 29] [Cited by in F6Publishing: 26] [Article Influence: 2.1] [Reference Citation Analysis]
17 Lester S, McLure C, Williamson J, Bardy P, Rischmueller M, Dawkins RL. Epistasis between the MHC and the RCA alpha block in primary Sjögren syndrome. Ann Rheum Dis 2008;67:849-54. [PMID: 17878210 DOI: 10.1136/ard.2007.075044] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 0.7] [Reference Citation Analysis]
18 Frank MM. CD21 deficiency, complement, and the development of common variable immunodeficiency. J Allergy Clin Immunol 2012;129:811-3. [PMID: 22277200 DOI: 10.1016/j.jaci.2011.12.982] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
19 Niewiesk S. Maternal antibodies: clinical significance, mechanism of interference with immune responses, and possible vaccination strategies. Front Immunol 2014;5:446. [PMID: 25278941 DOI: 10.3389/fimmu.2014.00446] [Cited by in Crossref: 219] [Cited by in F6Publishing: 202] [Article Influence: 27.4] [Reference Citation Analysis]
20 Gilbert HE, Asokan R, Holers VM, Perkins SJ. The 15 SCR Flexible Extracellular Domains of Human Complement Receptor Type 2 can Mediate Multiple Ligand and Antigen Interactions. Journal of Molecular Biology 2006;362:1132-47. [DOI: 10.1016/j.jmb.2006.08.012] [Cited by in Crossref: 29] [Cited by in F6Publishing: 28] [Article Influence: 1.8] [Reference Citation Analysis]
21 Ogembo JG, Kannan L, Ghiran I, Nicholson-Weller A, Finberg RW, Tsokos GC, Fingeroth JD. Human complement receptor type 1/CD35 is an Epstein-Barr Virus receptor. Cell Rep. 2013;3:371-385. [PMID: 23416052 DOI: 10.1016/j.celrep.2013.01.023] [Cited by in Crossref: 78] [Cited by in F6Publishing: 68] [Article Influence: 8.7] [Reference Citation Analysis]
22 Parvaneh N, Casanova JL, Notarangelo LD, Conley ME. Primary immunodeficiencies: a rapidly evolving story. J Allergy Clin Immunol 2013;131:314-23. [PMID: 23374262 DOI: 10.1016/j.jaci.2012.11.051] [Cited by in Crossref: 66] [Cited by in F6Publishing: 51] [Article Influence: 7.3] [Reference Citation Analysis]
23 Thiel J, Kimmig L, Salzer U, Grudzien M, Lebrecht D, Hagena T, Draeger R, Voelxen N, Bergbreiter A, Jennings S, Gutenberger S, Aichem A, Illges H, Hannan JP, Kienzler AK, Rizzi M, Eibel H, Peter HH, Warnatz K, Grimbacher B, Rump JA, Schlesier M. Genetic CD21 deficiency is associated with hypogammaglobulinemia. J Allergy Clin Immunol 2012;129:801-810.e6. [PMID: 22035880 DOI: 10.1016/j.jaci.2011.09.027] [Cited by in Crossref: 139] [Cited by in F6Publishing: 113] [Article Influence: 12.6] [Reference Citation Analysis]
24 Ren J, Liao X, Vieson MD, Chen M, Scott R, Kazmierczak J, Luo XM, Reilly CM. Selective HDAC6 inhibition decreases early stage of lupus nephritis by down-regulating both innate and adaptive immune responses. Clin Exp Immunol 2018;191:19-31. [PMID: 28876451 DOI: 10.1111/cei.13046] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 2.6] [Reference Citation Analysis]
25 Sekine H, Kinser TT, Qiao F, Martinez E, Paulling E, Ruiz P, Gilkeson GS, Tomlinson S. The benefit of targeted and selective inhibition of the alternative complement pathway for modulating autoimmunity and renal disease in MRL/lpr mice. Arthritis Rheum 2011;63:1076-85. [PMID: 21452327 DOI: 10.1002/art.30222] [Cited by in Crossref: 53] [Cited by in F6Publishing: 45] [Article Influence: 4.8] [Reference Citation Analysis]
26 Toepfner N, Cepok S, Grummel V, Hemmer B. The role of the Epstein–Barr Virus receptor CD21 in Multiple Sclerosis. Journal of Neuroimmunology 2012;242:47-51. [DOI: 10.1016/j.jneuroim.2011.11.002] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
27 Moriyama M, Fukuhara T, Britschgi M, He Y, Narasimhan R, Villeda S, Molina H, Huber BT, Holers M, Wyss-Coray T. Complement receptor 2 is expressed in neural progenitor cells and regulates adult hippocampal neurogenesis. J Neurosci 2011;31:3981-9. [PMID: 21411641 DOI: 10.1523/JNEUROSCI.3617-10.2011] [Cited by in Crossref: 66] [Cited by in F6Publishing: 36] [Article Influence: 6.0] [Reference Citation Analysis]
28 Hahn BH, Tsao BP. Pathogenesis of Systemic Lupus Erythematosus. Kelley's Textbook of Rheumatology. Elsevier; 2009. pp. 1233-62. [DOI: 10.1016/b978-1-4160-3285-4.10074-9] [Cited by in Crossref: 2] [Article Influence: 0.2] [Reference Citation Analysis]
29 Atkinson C, Qiao F, Song H, Gilkeson GS, Tomlinson S. Low-dose targeted complement inhibition protects against renal disease and other manifestations of autoimmune disease in MRL/lpr mice. J Immunol 2008;180:1231-8. [PMID: 18178863 DOI: 10.4049/jimmunol.180.2.1231] [Cited by in Crossref: 54] [Cited by in F6Publishing: 47] [Article Influence: 3.9] [Reference Citation Analysis]
30 Arredouani MS, Bhasin MK, Sage DR, Dunn LK, Gill MB, Agnani D, Libermann TA, Fingeroth JD. Analysis of host gene expression changes reveals distinct roles for the cytoplasmic domain of the Epstein-Barr virus receptor/CD21 in B-cell maturation, activation, and initiation of virus infection. J Virol 2014;88:5559-77. [PMID: 24600013 DOI: 10.1128/JVI.03099-13] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
31 Kovacs JM, Hannan JP, Eisenmesser EZ, Holers VM. Mapping of the C3d ligand binding site on complement receptor 2 (CR2/CD21) using nuclear magnetic resonance and chemical shift analysis. J Biol Chem 2009;284:9513-20. [PMID: 19164292 DOI: 10.1074/jbc.M808404200] [Cited by in Crossref: 18] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
32 Atkinson JP, Yu CY. The Complement System in Systemic Lupus Erythematosus. Systemic Lupus Erythematosus. Elsevier; 2016. pp. 81-112. [DOI: 10.1016/b978-0-12-801917-7.00012-7] [Cited by in Crossref: 3] [Article Influence: 0.5] [Reference Citation Analysis]
33 Kovacs JM, Hannan JP, Eisenmesser EZ, Holers VM. Biophysical investigations of complement receptor 2 (CD21 and CR2)-ligand interactions reveal amino acid contacts unique to each receptor-ligand pair. J Biol Chem 2010;285:27251-8. [PMID: 20558730 DOI: 10.1074/jbc.M110.106617] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
34 Holers VM, Kulik L. Complement receptor 2, natural antibodies and innate immunity: Inter-relationships in B cell selection and activation. Mol Immunol 2007;44:64-72. [PMID: 16876864 DOI: 10.1016/j.molimm.2006.07.003] [Cited by in Crossref: 38] [Cited by in F6Publishing: 36] [Article Influence: 2.4] [Reference Citation Analysis]
35 Ricklin D, Tzekou A, Garcia BL, Hammel M, McWhorter WJ, Sfyroera G, Wu YQ, Holers VM, Herbert AP, Barlow PN, Geisbrecht BV, Lambris JD. A molecular insight into complement evasion by the staphylococcal complement inhibitor protein family. J Immunol 2009;183:2565-74. [PMID: 19625656 DOI: 10.4049/jimmunol.0901443] [Cited by in Crossref: 46] [Cited by in F6Publishing: 45] [Article Influence: 3.5] [Reference Citation Analysis]
36 Sousa H, Bastos MJ, Ribeiro J, Oliveira S, Breda E, Catarino R, Medeiros R. 5'UTR +24T>C CR2 is not associated with nasopharyngeal carcinoma development in the North Region of Portugal. Oral Dis 2016;22:280-4. [PMID: 26748973 DOI: 10.1111/odi.12436] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
37 Liu C, Xuan Z. Prioritization of cancer-related genomic variants by SNP association network. Cancer Inform 2015;14:57-70. [PMID: 25995611 DOI: 10.4137/CIN.S17288] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
38 Holers VM, Rohrer B, Tomlinson S. CR2-mediated targeting of complement inhibitors: bench-to-bedside using a novel strategy for site-specific complement modulation. Adv Exp Med Biol 2013;735:137-54. [PMID: 23402024 DOI: 10.1007/978-1-4614-4118-2_9] [Cited by in Crossref: 38] [Cited by in F6Publishing: 40] [Article Influence: 4.2] [Reference Citation Analysis]
39 Twohig J, Kulik L, Haluszczak C, Reuter J, Rossbach A, Bull M, Holers VM, Marchbank KJ. Defective B cell ontogeny and immune response in human complement receptor 2 (CR2, CD21) transgenic mice is partially recovered in the absence of C3. Mol Immunol 2007;44:3434-44. [PMID: 17379312 DOI: 10.1016/j.molimm.2007.02.011] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
40 Young KA, Herbert AP, Barlow PN, Holers VM, Hannan JP. Molecular basis of the interaction between complement receptor type 2 (CR2/CD21) and Epstein-Barr virus glycoprotein gp350. J Virol 2008;82:11217-27. [PMID: 18786993 DOI: 10.1128/JVI.01673-08] [Cited by in Crossref: 27] [Cited by in F6Publishing: 14] [Article Influence: 1.9] [Reference Citation Analysis]
41 Sibilia J, Pasquali JL. [Systemic lupus erythematosus: news and therapeutic perspectives]. Presse Med 2008;37:444-59. [PMID: 18242045 DOI: 10.1016/j.lpm.2007.11.011] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
42 Thorarinsdottir K, Camponeschi A, Gjertsson I, Mårtensson IL. CD21 -/low B cells: A Snapshot of a Unique B Cell Subset in Health and Disease. Scand J Immunol 2015;82:254-61. [PMID: 26119182 DOI: 10.1111/sji.12339] [Cited by in Crossref: 41] [Cited by in F6Publishing: 40] [Article Influence: 5.9] [Reference Citation Analysis]
43 Hillyer P, Mane VP, Schramm LM, Puig M, Verthelyi D, Chen A, Zhao Z, Navarro MB, Kirschman KD, Bykadi S, Jubin RG, Rabin RL. Expression profiles of human interferon-alpha and interferon-lambda subtypes are ligand- and cell-dependent. Immunol Cell Biol 2012;90:774-83. [PMID: 22249201 DOI: 10.1038/icb.2011.109] [Cited by in Crossref: 71] [Cited by in F6Publishing: 71] [Article Influence: 7.1] [Reference Citation Analysis]
44 Asokan R, Banda NK, Szakonyi G, Chen XS, Holers VM. Human complement receptor 2 (CR2/CD21) as a receptor for DNA: implications for its roles in the immune response and the pathogenesis of systemic lupus erythematosus (SLE). Mol Immunol 2013;53:99-110. [PMID: 22885687 DOI: 10.1016/j.molimm.2012.07.002] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 2.2] [Reference Citation Analysis]
45 Holers VM, Tomlinson S, Kulik L, Atkinson C, Rohrer B, Banda N, Thurman JM. New therapeutic and diagnostic opportunities for injured tissue-specific targeting of complement inhibitors and imaging modalities. Semin Immunol 2016;28:260-7. [PMID: 27282113 DOI: 10.1016/j.smim.2016.05.007] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 2.5] [Reference Citation Analysis]
46 Herrero R, Real LM, Rivero-Juárez A, Pineda JA, Camacho Á, Macías J, Laplana M, Konieczny P, Márquez FJ, Souto JC, Soria JM, Saulle I, Lo Caputo S, Biasin M, Rivero A, Fibla J, Caruz A. Association of complement receptor 2 polymorphisms with innate resistance to HIV-1 infection. Genes Immun 2015;16:134-41. [PMID: 25569262 DOI: 10.1038/gene.2014.71] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
47 Banda NK, Levitt B, Glogowska MJ, Thurman JM, Takahashi K, Stahl GL, Tomlinson S, Arend WP, Holers VM. Targeted inhibition of the complement alternative pathway with complement receptor 2 and factor H attenuates collagen antibody-induced arthritis in mice. J Immunol 2009;183:5928-37. [PMID: 19828624 DOI: 10.4049/jimmunol.0901826] [Cited by in Crossref: 48] [Cited by in F6Publishing: 51] [Article Influence: 3.7] [Reference Citation Analysis]
48 Gies V, Schickel JN, Jung S, Joublin A, Glauzy S, Knapp AM, Soley A, Poindron V, Guffroy A, Choi JY, Gottenberg JE, Anolik JH, Martin T, Soulas-Sprauel P, Meffre E, Korganow AS. Impaired TLR9 responses in B cells from patients with systemic lupus erythematosus. JCI Insight 2018;3:96795. [PMID: 29515028 DOI: 10.1172/jci.insight.96795] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 6.3] [Reference Citation Analysis]
49 Pringle ES, Firth MA, Chattha KS, Hodgins DC, Shewen PE. Expression of complement receptors 1 (CR1/CD35) and 2 (CR2/CD21), and co-signaling molecule CD19 in cattle. Dev Comp Immunol 2012;38:487-94. [PMID: 22989997 DOI: 10.1016/j.dci.2012.08.003] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
50 Pestka S. The interferons: 50 years after their discovery, there is much more to learn. J Biol Chem 2007;282:20047-51. [PMID: 17502369 DOI: 10.1074/jbc.R700004200] [Cited by in Crossref: 247] [Cited by in F6Publishing: 110] [Article Influence: 16.5] [Reference Citation Analysis]
51 Scagnolari C, Antonelli G. Type I interferon and HIV: Subtle balance between antiviral activity, immunopathogenesis and the microbiome. Cytokine Growth Factor Rev 2018;40:19-31. [PMID: 29576284 DOI: 10.1016/j.cytogfr.2018.03.003] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 4.5] [Reference Citation Analysis]
52 Zhang J, Zhang L, Zhang Y, Yang J, Guo M, Sun L, Pan H, Hirankarn N, Ying D, Zeng S, Lee TL, Lau CS, Chan TM, Leung AMH, Mok CC, Wong SN, Lee KW, Ho MHK, Lee PPW, Chung BH, Chong CY, Wong RWS, Mok MY, Wong WHS, Tong KL, Tse NKC, Li X, Avihingsanon Y, Rianthavorn P, Deekajorndej T, Suphapeetiporn K, Shotelersuk V, Ying SKY, Fung SKS, Lai WM, Garcia-barceló M, Cherny SS, Sham PC, Cui Y, Yang S, Ye DQ, Zhang X, Lau YL, Yang W. Gene-Based Meta-Analysis of Genome-Wide Association Study Data Identifies Independent Single-Nucleotide Polymorphisms in ANXA6 as Being Associated With Systemic Lupus Erythematosus in Asian Populations: ASSOCIATION OF ANXA6 WITH SLE IN ASIANS. Arthritis & Rheumatology 2015;67:2966-77. [DOI: 10.1002/art.39275] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
53 Edkins AL, Borland G, Acharya M, Cogdell RJ, Ozanne BW, Cushley W. Differential regulation of monocyte cytokine release by αV and β(2) integrins that bind CD23. Immunology 2012;136:241-51. [PMID: 22348662 DOI: 10.1111/j.1365-2567.2012.03576.x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
54 Rich RL, Myszka DG. Survey of the year 2006 commercial optical biosensor literature. J Mol Recognit 2007;20:300-66. [DOI: 10.1002/jmr.862] [Cited by in Crossref: 94] [Cited by in F6Publishing: 77] [Article Influence: 6.3] [Reference Citation Analysis]
55 Quan TE, Roman RM, Rudenga BJ, Holers VM, Craft JE. Epstein-Barr virus promotes interferon-alpha production by plasmacytoid dendritic cells. Arthritis Rheum 2010;62:1693-701. [PMID: 20178121 DOI: 10.1002/art.27408] [Cited by in Crossref: 57] [Cited by in F6Publishing: 51] [Article Influence: 4.8] [Reference Citation Analysis]
56 Seelig DM, Avery P, Webb T, Yoshimoto J, Bromberek J, Ehrhart EJ, Avery AC. Canine T-zone lymphoma: unique immunophenotypic features, outcome, and population characteristics. J Vet Intern Med 2014;28:878-86. [PMID: 24655022 DOI: 10.1111/jvim.12343] [Cited by in Crossref: 71] [Cited by in F6Publishing: 65] [Article Influence: 8.9] [Reference Citation Analysis]